FIELD: chemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody to adrenomedullin or its antigen-binding fragment. This antibody or antigen-binding fragment thereof specifically binds to the N-terminal region (ac-1-21) of mature human ADM having the sequence YRQSMNNFQGLRSFGCRFGTC, represented as SEQ ID NO: 23, and has an affinity binding to ADM of at least 10-7 M. Pharmaceutical combination is also provided for use as a medicament for stabilizing the circulation and comprising an effective amount of said antibody or antigen-binding fragment thereof and a vasoconstrictor, for example catecholamine. Pharmaceutical combination is proposed for use as a medicament for controlling a fluid balance and comprising an effective amount of said antibody or antigen-binding fragment thereof and an intravenous fluid. Pharmaceutical combination is proposed for use as a medicament for the treatment of sepsis and comprising an effective amount of said antibody or antigen-binding fragment thereof and an antibody to TNF-alpha. Also provided is a pharmaceutical composition for regulating a patient's fluid balance comprising an effective amount of said antibody or antigen-binding fragment thereof and a pharmaceutically acceptable excipient.
EFFECT: pharmaceutical combination is provided for use as a medicament for the treatment of sepsis and comprising an effective amount of said antibody or antigen-binding fragment thereof and antibiotics.
14 cl, 24 dwg, 12 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT | 2017 |
|
RU2762059C2 |
ADRENOMEDULLIN (ADM) FOR DIAGNOSTICS AND/OR PREDICTION OF DEMENTIA AND ANTIADRENOMEDULLIN-BINDING AGENT FOR USE IN THERAPY OR PREVENTION OF DEMENTIA | 2019 |
|
RU2811309C2 |
THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) | 2018 |
|
RU2776811C2 |
COMPOUND BINDING ADRENOMEDULLIN (ADM) FOR USE FOR THERAPY OR PREVENTION OF DISEASE SYMPTOMS | 2018 |
|
RU2790561C2 |
ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | 2014 |
|
RU2673455C2 |
ANTI-IL-17 ANTIBODIES, METHODS OF THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2577228C2 |
ANTI-MIF ANTIBODIES | 2008 |
|
RU2509777C2 |
APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
ADRENOMEDULLIN ASSAY AND METHODS FOR DETERMINING MATURE ADRENOMEDULLIN | 2012 |
|
RU2657517C2 |
Authors
Dates
2018-07-26—Published
2012-11-16—Filed